Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SAR443820 in multiple sclerosis
2023-509078-45-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing SAR443820 with Placebo → SAR443820 (2 arms). Primary endpoints: Part A: Week 48 sNfL levels relative to baseline and Part B: Week 96 sNfL levels relative to baseline. Started Apr 2024; status: completed.
02
Drugs
oditrasertib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2023-509078-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509078-45-00.